These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 38647975)

  • 1. Sustained Improvements in Clinical and Patient-Reported Outcomes and Quality of Life Through 5 Years Among Ixekizumab-Treated Patients with Complete Clearance of Scalp Psoriasis by Week 60.
    Egeberg A; Hawkes JE; Somani N; Burge R; See K; Gallo G; McKean-Matthews M; Gooderham M; Han G; Armstrong A
    Dermatol Ther (Heidelb); 2024 Apr; 14(4):1007-1018. PubMed ID: 38647975
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Brodalumab and ixekizumab, anti-interleukin-17-receptor antibodies for psoriasis: a critical appraisal.
    Spuls PI; Hooft L
    Br J Dermatol; 2012 Oct; 167(4):710-3; discussion 714-5. PubMed ID: 23013312
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sustained response with ixekizumab treatment of moderate-to-severe psoriasis with scalp involvement: results from three phase 3 trials (UNCOVER-1, UNCOVER-2, UNCOVER-3).
    Reich K; Leonardi C; Lebwohl M; Kerdel F; Okubo Y; Romiti R; Goldblum O; Dennehy EB; Kerr L; Sofen H
    J Dermatolog Treat; 2017 Jun; 28(4):282-287. PubMed ID: 27759463
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Higher rates of skin clearance and efficacy in challenging body areas are associated with better health-related quality of life following ixekizumab maintenance treatment in pediatric patients with plaque psoriasis.
    Hebert AA; Bobonich MA; Rodriguez Capriles C; Gallo G; Li L; Somani N; Ridenour T; Wang Y; Edson-Heredia E; Becker EM
    Pediatr Dermatol; 2022 Jan; 39(1):55-60. PubMed ID: 34931346
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term Efficacy and Safety of Up to 108 Weeks of Ixekizumab in Pediatric Patients With Moderate to Severe Plaque Psoriasis: The IXORA-PEDS Randomized Clinical Trial.
    Paller AS; Seyger MMB; Magariños GA; Pinter A; Cather JC; Rodriguez-Capriles C; Zhu D; Somani N; Garrelts A; Papp KA;
    JAMA Dermatol; 2022 May; 158(5):533-541. PubMed ID: 35416908
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and Safety of Ixekizumab Through 5 Years in Moderate-to-Severe Psoriasis: Long-Term Results from the UNCOVER-1 and UNCOVER-2 Phase-3 Randomized Controlled Trials.
    Leonardi C; Reich K; Foley P; Torii H; Gerdes S; Guenther L; Gooderham M; Ferris LK; Griffiths CEM; ElMaraghy H; Crane H; Patel H; Burge R; Gallo G; Shrom D; Leung A; Lin CY; Papp K
    Dermatol Ther (Heidelb); 2020 Jun; 10(3):431-447. PubMed ID: 32200512
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of Ixekizumab on Patient Reported Outcomes and Quality of Life in Patients With Moderate-to-Severe Plaque Psoriasis: 5-Year Results from the UNCOVER-1 and -2 Studies.
    Gooderham MJ; Elewski B; Augustin M; Iversen L; Torii H; Burge R; See K; Gallo G; Eastman WJ; McKean-Matthews M; Foley P
    J Drugs Dermatol; 2021 Apr; 20(4):394-401. PubMed ID: 33852247
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of ixekizumab in a phase III, randomized, double-blind, placebo-controlled study in paediatric patients with moderate-to-severe plaque psoriasis (IXORA-PEDS).
    Paller AS; Seyger MMB; Alejandro Magariños G; Bagel J; Pinter A; Cather J; Keller S; Rodriguez Capriles C; Gontijo Lima R; Gallo G; Little CA; Edson-Heredia E; Li L; Xu W; Papp K;
    Br J Dermatol; 2020 Aug; 183(2):231-241. PubMed ID: 32316070
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Improvement of scalp and nail lesions with ixekizumab in a phase 2 trial in patients with chronic plaque psoriasis.
    Langley RG; Rich P; Menter A; Krueger G; Goldblum O; Dutronc Y; Zhu B; Wei H; Cameron GS; Heffernan MP
    J Eur Acad Dermatol Venereol; 2015 Sep; 29(9):1763-70. PubMed ID: 25693783
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sustained High Efficacy and Favorable Safety Over Five Years in Patients With Burdensome Psoriasis (UNCOVER-1/UNCOVER-2).
    Papp KA; Gerdes S; Leonardi CL; Elmaraghy H; See K; McKean-Matthews M; Konicek BW; Crane HM; Eastman W
    J Drugs Dermatol; 2021 Aug; 20(8):880-887. PubMed ID: 34397207
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Relationship Between Rapid Skin Clearance and Quality of Life Benefit: Post Hoc Analysis of Japanese Patients with Moderate-to-Severe Psoriasis Treated with Ixekizumab (UNCOVER-J).
    Honma M; Cai Z; Burge R; Zhu B; Yotsukura S; Torisu-Itakura H
    Dermatol Ther (Heidelb); 2020 Dec; 10(6):1397-1404. PubMed ID: 32910360
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of Ixekizumab Treatment on Work Productivity for Patients With Moderate-to-Severe Plaque Psoriasis: Analysis of Results From 3 Randomized Phase 3 Clinical Trials.
    Armstrong AW; Lynde CW; McBride SR; Ståhle M; Edson-Heredia E; Zhu B; Amato D; Nikaï E; Yang FE; Gordon KB
    JAMA Dermatol; 2016 Jun; 152(6):661-9. PubMed ID: 26953848
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and Safety of Switching to Ixekizumab in Etanercept Non-Responders: A Subanalysis from Two Phase III Randomized Clinical Trials in Moderate-to-Severe Plaque Psoriasis (UNCOVER-2 and -3).
    Blauvelt A; Papp KA; Griffiths CEM; Puig L; Weisman J; Dutronc Y; Kerr LF; Ilo D; Mallbris L; Augustin M
    Am J Clin Dermatol; 2017 Apr; 18(2):273-280. PubMed ID: 28074446
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of Ixekizumab Treatment on Itch and Psoriasis Area and Severity Index in Patients with Moderate-to-Severe Plaque Psoriasis: An Integrated Analysis of Two Phase III Randomized Studies.
    Yosipovitch G; Reich A; Steinhoff M; Beselin A; Kent T; Dossenbach M; Berggren L; Henneges C; Luger T
    Dermatol Ther (Heidelb); 2018 Dec; 8(4):621-637. PubMed ID: 30465321
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase 3 Trials of Ixekizumab in Moderate-to-Severe Plaque Psoriasis.
    Gordon KB; Blauvelt A; Papp KA; Langley RG; Luger T; Ohtsuki M; Reich K; Amato D; Ball SG; Braun DK; Cameron GS; Erickson J; Konrad RJ; Muram TM; Nickoloff BJ; Osuntokun OO; Secrest RJ; Zhao F; Mallbris L; Leonardi CL; ; ;
    N Engl J Med; 2016 Jul; 375(4):345-56. PubMed ID: 27299809
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials.
    Griffiths CE; Reich K; Lebwohl M; van de Kerkhof P; Paul C; Menter A; Cameron GS; Erickson J; Zhang L; Secrest RJ; Ball S; Braun DK; Osuntokun OO; Heffernan MP; Nickoloff BJ; Papp K;
    Lancet; 2015 Aug; 386(9993):541-51. PubMed ID: 26072109
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of ixekizumab compared to etanercept and placebo in patients with moderate-to-severe plaque psoriasis and non-pustular palmoplantar involvement: results from three phase 3 trials (UNCOVER-1, UNCOVER-2 and UNCOVER-3).
    Menter A; Warren RB; Langley RG; Merola JF; Kerr LN; Dennehy EB; Shrom D; Amato D; Okubo Y; Reich K
    J Eur Acad Dermatol Venereol; 2017 Oct; 31(10):1686-1692. PubMed ID: 28322474
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Simultaneous Nail and Skin Clearance in Ixekizumab Head-to-Head Trials for Moderate-to-Severe Psoriasis and Psoriatic Arthritis.
    Elewski BE; Blauvelt A; Gallo G; Wolf E; McKean-Matthews M; Burge R; Merola JF; Gottlieb AB; Guenther LC
    Dermatol Ther (Heidelb); 2022 Apr; 12(4):911-920. PubMed ID: 35279805
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A head-to-head comparison of ixekizumab vs. guselkumab in patients with moderate-to-severe plaque psoriasis: 12-week efficacy, safety and speed of response from a randomized, double-blinded trial.
    Blauvelt A; Papp K; Gottlieb A; Jarell A; Reich K; Maari C; Gordon KB; Ferris LK; Langley RG; Tada Y; Lima RG; Elmaraghy H; Gallo G; Renda L; Park SY; Burge R; Bagel J;
    Br J Dermatol; 2020 Jun; 182(6):1348-1358. PubMed ID: 31887225
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rapid improvements in health-related quality of life and itch with ixekizumab treatment in randomized phase 3 trials: results from UNCOVER-2 and UNCOVER-3.
    Leonardi CL; Blauvelt A; Sofen HL; Gooderham M; Augustin M; Burge R; Zhu B; Reich K
    J Eur Acad Dermatol Venereol; 2017 Sep; 31(9):1483-1490. PubMed ID: 28294430
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.